# Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

> **NCT03616470** · PHASE3 · TERMINATED · sponsor: **GlycoMimetics Incorporated** · enrollment: 388 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Uproleselan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03616470
- **Lead sponsor:** GlycoMimetics Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-15
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 388 (ACTUAL)
- **Why stopped:** Trial failed to meet primary endpoint.
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03616470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03616470, "Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03616470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*